• +1-646-491-9876
    • +91-20-67278686

    Search

    Birch Pollen Allergy - Pipeline Review, H1 2017

    Birch Pollen Allergy - Pipeline Review, H1 2017

    • Report Code ID: RW0001689403
    • Category Healthcare
    • No. of Pages 41
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Birch Pollen Allergy - Pipeline Review, H1 2017, provides an overview of the Birch Pollen Allergy (Immunology) pipeline landscape.

    Birch pollen allergy is a reaction which occurs soon after exposure to pollen of birch trees. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies. Treatment includes drugs belonging to class of antihistamines.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Birch Pollen Allergy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Birch Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Birch Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 2, 1 and 1 respectively.

    Birch Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy (Immunology).
    - The pipeline guide reviews pipeline therapeutics for Birch Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Birch Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Birch Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Birch Pollen Allergy (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Birch Pollen Allergy (Immunology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Birch Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Birch Pollen Allergy - Overview
    Birch Pollen Allergy - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Birch Pollen Allergy - Therapeutics Assessment
    Assessment by Target
    Assessment by Route of Administration
    Assessment by Molecule Type
    Birch Pollen Allergy - Companies Involved in Therapeutics Development
    ALK-Abello A/S
    Anergis SA
    Biomay AG
    Circassia Pharmaceuticals Plc
    HAL Allergy BV
    Laboratorios LETI SL
    Birch Pollen Allergy - Drug Profiles
    Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AllerT - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BM-31 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PL-102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Birch Pollen Allergy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Birch Pollen Allergy - Dormant Projects
    Birch Pollen Allergy - Discontinued Products
    Birch Pollen Allergy - Product Development Milestones
    Featured News & Press Releases
    Feb 08, 2017: Anergis Completes Patient Recruitment In Large-Scale ATIBAR Trial With Ultra-Fast Allergy Immunotherapy AllerT
    Jun 07, 2016: Anergis to Present New Data on Lead Compound AllerT at the 35th European Academy of Allergy and Clinical Immunology Congress 2016
    May 17, 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy
    Jun 04, 2015: Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015
    Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial
    Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen
    Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting
    Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT
    Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT
    May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen
    Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT
    Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego
    Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT
    Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT
    Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Birch Pollen Allergy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2017
    Birch Pollen Allergy - Pipeline by Anergis SA, H1 2017
    Birch Pollen Allergy - Pipeline by Biomay AG, H1 2017
    Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2017
    Birch Pollen Allergy - Pipeline by HAL Allergy BV, H1 2017
    Birch Pollen Allergy - Pipeline by Laboratorios LETI SL, H1 2017
    Birch Pollen Allergy - Dormant Projects, H1 2017
    Birch Pollen Allergy - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Birch Pollen Allergy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    ALK-Abello A/S
    Anergis SA
    Biomay AG
    Circassia Pharmaceuticals Plc
    HAL Allergy BV
    Laboratorios LETI SL

    Request for Sample

    Report Url http://www.reportsweb.com//birch-pollen-allergy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//birch-pollen-allergy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//birch-pollen-allergy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments